Ucommune International Azioni (NASDAQ: UK)

Ultime notizie per Ucommune International (NASDAQ:UK) Azioni

Ucommune International

Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. They provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.

Ucommune International Ltd - Ordinary Shares

Ucommune International Ltd

UK OIL & GAS INVTS PLC by UK Oil & Gas Invts Plc

Ucommune International Ltd - Warrant expiring 11/17/2025

<p>The U.S. can't repay its $36 trillion of debt.</p>
<p>Here's what will happen instead:</p>
<p><figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="307" height="164" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30174818/image-1-2.jpeg" alt="" class="wp-image-12012" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30174818/image-1-2.jpeg 307w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/30174818/image-1-2-300x160.jpeg 300w" sizes="(max-width: 307px) 100vw, 307px" /></figure></p>
<p>There are only 3 possible outcomes to addressing the debt problem:</p>
<p>1 &#8211; Default</p>
<p>2 &#8211; Print the debt away</p>
<p>3 &#8211; Technological &amp; deflationary boom</p>
<p>Let's look at all 3 </p>
<p>1 &#8211; Default</p>
<p>If the U.S. decides not to pay back its debt, the consequences would be massive.</p>
<p>The entire system is built on trust…and defaulting would destroy all trust in the U.S.</p>
<p>The dollar would collapse, credit markets would freeze, and financial panic would ensue.</p>
<p>It would be a Great Depression 2.0-style event.</p>
<p>2 &#8211; Print</p>
<p>If the U.S. printed its debt away, we'd experience extreme inflation.</p>
<p>Possibly Weimar Republic or Zimbabwe levels of inflation.</p>
<p>Basic necessities would be unaffordable. Not fun.</p>
<p>3 &#8211; Technological &amp; deflationary boom</p>
<p>New technology could theoretically boost productivity to the point where the economy outgrows its debt.</p>
<p>Tech is deflationary because it increases productivity and reduces costs over time.</p>
<p>Many believe that AI, cryptocurrency, and humanoid robots are the deflating counterbalance we need to combat our debt.</p>
<p>So what exactly will happen?</p>
<p>Likely a combination of short to medium-term money printing.</p>
<p>Followed by a long-term solution of technological innovation.</p>
<p>The U.S. dollar likely won't spiral into irrelevancy like many believe.</p>
<p>The British pound was once the reserve currency. Today, it's still the 5th most economically relevant currency on earth.</p>
<p>The dollar could experience a similar fate…while tech digs us out of this hole we're in.</p>
<p>But no matter what happens, one thing is for certain:</p>
<p>The dollar is the measuring stick we use to value asset prices.</p>
<p>And as that measuring stick erodes, asset prices will nominally rise.</p>
<p>So buy assets, or get left behind.</p>
<p>&#x2A;&#x2A;</p>
<p><em>Hey there!</em></p>
<p><em>Welcome to the WOLF Financial Newsletter.</em></p>
<p><em>Join over 13,000 savvy investors building wealth and mastering advanced investing strategies live on Twitter Spaces. Subscribe below to be part of the action:</em></p>
<p><a href="https://marketmadness-newsletter.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Subscribe</a></p>
<p><em>WOLF Financial has driven liquidity, user growth, and brand awareness across TradFi and Crypto through marketing, advisory, and partnership services. See more&nbsp;<a href="https://wolf.financial/?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=will-the-us-ever-pay-off-its-debt" target="_blank" rel="noreferrer noopener">Here</a>.</em></p>


Equities

Government

Opinion

Markets

Trading Ideas

ETFs

Will The US Ever Pay Off Its Debt? Here's Why We Think It Won't…

<p>Maxim Group  analyst Allen Klee   initiates coverage on Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) with a Buy rating and announces Price Target of $5.</p>


News

Price Target

Initiation

Analyst Ratings

OXBR

Maxim Group Initiates Coverage On Oxbridge Re Holdings with Buy Rating, Announces Price Target of $5

<p><strong>UBS Group AG&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>)&nbsp;shares are trading lower on Wednesday. The Swiss bank reported&nbsp;first-quarter 2025 sales of&nbsp;$12.56 billion. This marked a 1% year-over-year decline and <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">fell short of the $12.99 billion consensus estimate</a>.</p>
<p>Underlying revenues declined slightly&nbsp;Y/Y to&nbsp;$11.9 billion.&nbsp;Underlying revenues from the core businesses rose 6% Y/Y, while revenues in the much-reduced Noncore and Legacy division declined 72% Y/Y.</p>
<p>Underlying operating profit before tax reached&nbsp;$2.59 billion, down 1%&nbsp;Y/Y in the quarter.</p>
<p>Global Wealth&nbsp;Management's&nbsp;net new assets for the&nbsp;quarter were&nbsp;$32 billion, with revenues rising&nbsp;<a target="_blank" href="https://www.ubs.com/global/en/investor-relations/press-releases/overview-news-display-ndp/en-20250430-1q25-quarterly-result.html?caasID=CAAS-ActivityStream" rel="noreferrer noopener">5</a>%&nbsp;Y/Y to&nbsp;$6.25 billion.</p>
<p>The group posted a net profit attributable to shareholders of&nbsp;$1.69 billion&nbsp;for the quarter vs. $1.76 billion a year ago quarter. EPS&nbsp;of&nbsp;51 cents&nbsp;beat the consensus of&nbsp;41 cents.</p>
<p>The CET1 capital ratio, a measure of bank liquidity, was&nbsp;14.3%, compared to 14.8% in the year-ago quarter.</p>
<p>UBS CEO&nbsp;<strong>Sergio P. Ermotti</strong> stated, "The power and scale of our diversified global franchise, coupled with our continued focus on clients, drove strong business momentum in the quarter and net new inflows in our asset-gathering businesses."</p>
<p>"With increased uncertainty in markets and the macroeconomic outlook, we continue to focus on supporting clients, delivering on our financial targets, and acting as an engine of economic growth in the communities we serve."</p>
<p><strong>Buyback: </strong>The bank completed share buybacks&nbsp;worth $0.5 billion and reserved $2.5 billion for planned share repurchases for the remainder of 2025.</p>
<p><strong>Outlook:</strong> In the second quarter, UBS anticipates a low-single-digit percentage sequential decline in net interest income (NII) within Global Wealth Management and a similar decrease in Swiss franc terms <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">for Personal &amp; Corporate Banking's NII</a>.</p>
<p>Meanwhile, Personal &amp; Corporate Banking's NII is expected to increase sequentially by a mid-single-digit percentage in USD terms.</p>
<p>The bank noted that the continued market uncertainty could potentially delay the execution of their Global Banking pipeline.</p>
<p>Pull-to-par revenues are projected to reach $0.6 billion, which is anticipated to offset the expected $1.1 billion in integration-related expenses partly.</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>the Avantis International Equity ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVDE#NYSE">AVDE</a>) and&nbsp;<strong>the Elevation Series Trust The Opal International Dividend Income ETF&nbsp;</strong>(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IDVZ#BATS">IDVZ</a>).</p>
<p><strong>Price Action:&nbsp;</strong>UBS shares are down&nbsp;1.57%&nbsp;at&nbsp;$30.03 at the last check Wednesday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><em><a href="https://www.benzinga.com//node/44762037" target="_blank" rel="noreferrer noopener">Morgan Stanley Q1 Credit Loss Provision Jumps To $135 Million On ‘Weakening Macroeconomic Forecast,' Equity Revenue Jumps 45%</a></em></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Earnings

Large Cap

Guidance

Eurozone

Movers

AVDE

Elevation Series Trust The Opal International Dividend Income ETF

IDVZ

Why Is UBS Stock Trading Lower On Wednesday?

<p><strong>Eli Lilly And Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=LLY" target="_blank" rel="noreferrer noopener"> before market hours</a>.</p>
<p>The stock is up 14.35% over the past year, 14.79% YTD.</p>
<p>Let&#8217;s examine the charts for Eli Lilly stock and how it currently compares to Wall Street estimates.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/insights/news/25/04/45024735/1000-invested-in-this-stock-20-years-ago-would-be-worth-this-much-today">$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today</a></strong></p>
<h2 class="wp-block-heading">LLY Stock Chart Strongly Bullish Ahead Of Q1 Earnings</h2>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30125527/Screenshot-2025-04-30-at-10.24.51-PM.png" alt="" class="wp-image-895429" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30125527/Screenshot-2025-04-30-at-10.24.51-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30125527/Screenshot-2025-04-30-at-10.24.51-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure></p>
<p><em><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a></em></p>
<p>Eli Lilly&#8217;s stock is flashing a strongly bullish technical setup, with its stock at $896.20, trading well above key moving averages across the board. Specifically, the company&#8217;s stock is comfortably positioned above its five-day, 20-day and 50-day exponential moving averages, signaling firm upward momentum and sustained buying interest.</p>
<p>The stock also trades above its eight-day simple moving average (SMA) of $859.74, its 20-day SMA of $798.34 and its 50-day SMA of $834.64 &#8211; all clear bullish signals indicating technical strength.</p>
<p>Adding further support, Eli Lilly remains above its 200-day SMA of $844.59, a long-term bullish indicator watched closely by institutional investors. The Moving Average Convergence Divergence (MACD) reading stands at 18.97, reinforcing the bullish momentum with a positive divergence.</p>
<p>Meanwhile, the Relative Strength Index (RSI) of 64.49 shows the stock is not yet overbought, suggesting room for continued upside. For investors, the technical setup suggests confidence in the trend, with potential for further gains if broader market sentiment cooperates.</p>
<h2 class="wp-block-heading">Eli Lilly Analysts See 3% Upside</h2>
<p><strong>Ratings &amp; Consensus Estimates:</strong><a href="https://www.benzinga.com/quote/NFLX/analyst-ratings"> The consensus analyst rating</a> on Eli Lilly stock stands at a Buy currently with a price target of $945.70. The latest analyst ratings from HSBC, Cantor Fitzgerald and Guggenheim imply a 2.95% downside for Eli Lilly stock, with an average price target of $867.67.</p>
<p><strong>Price Action: </strong>Eli Lilly stock was trading at $895.25 at the time of publication.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/biotech/25/04/45078101/eli-lilly-set-to-report-earnings-as-investors-eye-weight-loss-drug-momentum">Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Biotech

Health Care

Technicals

Previews

General

Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?

<p><strong>First Solar, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares are trading lower on Wednesday after the company reported worse-than-expected earnings for the first quarter and cut its <a href="https://in.benzinga.com/news/earnings/25/04/45085368/first-solar-falls-short-on-q1-earnings-cuts-fy-guidance-due-to-tariffs-shares-tumble">full-year outlook</a>.</p>
<p><strong>What To Know:</strong> First Solar reported first-quarter earnings per share of $1.95, missing analyst estimates of $2.63. In addition, the solar company reported sales of $844.57 million, beating analyst estimates of $839.28 million, despite being down $700 million from the prior quarter.</p>
<p><strong>Outlook:</strong> The company also cut its full-year 2025 guidance. First Solar previously projected earnings per share between $17 and $20, but said it now expects earnings per share of $12.50 to $17.50, below analyst estimates of $18.20.</p>
<p>The company also lowered its sales guidance from between $5.30 billion to $5.80 billion to a new range of between $4.50 billion to $5.50 billion, versus analyst estimates of $5.46 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p>&#8220;Despite the near-term challenges presented by the new tariff regime, we believe that the long-term&nbsp;outlook&nbsp;for solar demand, particularly in our core U.S. market, remains strong, and that First Solar remains well-positioned to serve this demand,&#8221; said <strong>Mark Widmar</strong>, CEO. </p>
<p>&#8220;This belief is based on the unique profile of First Solar compared to its peers, as America&#8217;s largest, and most established solar module manufacturer, and the country&#8217;s only fully vertically integrated producer, our significant network of domestic supply chain vendors, and our proprietary CadTel-based semiconductor.&#8221;</p>
<p><strong>Analyst Changes:</strong> Following the earnings report, Keybanc downgraded First Solar to Underweight and set a new price target of $100 and Oppenheimer analysts downgraded the stock to Perform. Multiple analyst firms also lowered <a href="https://www.benzinga.com/insights/analyst-ratings/25/04/45100958/a-glimpse-into-the-expert-outlook-on-first-solar-through-21-analysts">price targets</a>.</p>
<ul>
<li>Wells Fargo analyst Michael Blum maintained an Overweight rating on First Solar and lowered the price target from $191 to $177.</li>
<li>RBC Capital analyst Christopher Dendrinos maintained an Outperform rating on First Solar and lowered the price target from $237 to $214.</li>
<li>BMO Capital analyst Ameet Thakkar maintained an Outperform rating on First Solar and lowered the price target from $200 to $187.</li>
<li>Goldman Sachs analyst Brian Lee maintained a Buy rating and lowered the price target from $235 to $204.</li>
</ul>
<p><strong>FSLR Price Action:</strong> At the time of publication, First Solar stock was down 9.74% at $123.88, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/25/04/45108703/fresh-del-monte-stock-falls-as-q1-sales-earnings-miss-expectations">Fresh Del Monte Stock Falls As Q1 Sales, Earnings Miss Expectations</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em>.</p>


Downgrades

FSLR

First Solar Stock Is Facing Heavy Selling Pressure Wednesday: What's Going On?

<p><strong>Ionis Pharmaceuticals Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of a $1.12 loss</a>.</p>
<p>Revenue increased 10% in the first quarter of 2025 to $132 million, beating the consensus of $125.32 million, driven by <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45095541/ionis-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">higher commercial revenue</a>.</p>
<ul>
<li>Tryngolza&nbsp;(olezarsen), the first-ever treatment for familial chylomicronemia syndrome as an adjunct to diet, generated net product sales of over&nbsp;$6 million&nbsp;in its first full quarter following approval in the&nbsp;U.S.&nbsp;on&nbsp;Dec. 19, 2024. A European approval decision is anticipated in the second half of 2025.</li>
<li>Wainua (eplontersen) (Wainzua in the EU) for polyneuropathy of hereditary transthyretin-mediated amyloidosis generated sales of $39 million, resulting in royalty revenue of $9 million in the first quarter of 2025.</li>
<li>Spinraza (nusinersen) for spinal muscular atrophy generated global sales of&nbsp;$424 million, resulting in royalty revenue of&nbsp;$48 million&nbsp;in the first quarter of 2025.
<ul>
<li>Higher dose nusinersen is under review for marketing approval in the U.S. (PDUFA date of Sept. 22, 2025) and the EU.</li>
</ul>
</li>
</ul>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44672086/rna-drugmaker-ionis-pharmaceuticals-highlighted-for-deep-pipeline-and-cash-flow-analyst-initiates-with-bullish-tone" rel="noreferrer noopener">Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For &#8216;Pipeline Depth&#8217;</a></strong></p>
<p>"We are increasing our 2025 financial guidance, including raising revenue guidance by more than 20 percent due to our strong first quarter results and recent successful licensing transactions. We are also substantially improving our operating loss and cash guidance &#8230; Our strong financial position and commitment to drive operating leverage position Ionis to advance our strategic priorities and successfully navigate the dynamic macroeconomic environment," said&nbsp;<strong>Elizabeth L. Hougen</strong>, Ionis chief financial officer.</p>
<p> "Moving forward, the three additional independent launches anticipated over the next couple of years position Ionis to deliver substantial and growing product revenue. This product revenue coupled with anticipated increasing royalty revenue from multiple partner launches and disciplined investment, position Ionis to achieve sustained positive cash flow,&#8221; Hougen added.</p>
<p><strong>Guidance:</strong>&nbsp;Ionis Pharmaceuticals forecasts 2025 revenue of $725-$750 million <a href="https://www.benzinga.com/25/02/43818962/ionis-pharmaceuticals-says-2024-revenue-exceeds-guidance-on-sales-from-diverse-sources-forecasts-over-600-million-in-2025-sales" target="_blank" rel="noreferrer noopener">compared to prior guidance</a> of over $600 million and the consensus of $659.37 million.</p>
<p>The company expects a 2025 adjusted operating loss of less than $375 million compared to prior guidance of less than $495 million, with cash, cash equivalents, and short-term investments of ~$1.9 billion (vs. ~$1.7 billion expected earlier).</p>
<p><strong>IONS Price Action: </strong>Ionis stock is up 2.01% at $30.41 at publication on Wednesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/25/04/45106948/norwegian-cruise-line-tumbles-after-earnings-miss-still-confident-in-2025-guidance" target="_blank" rel="noreferrer noopener">Norwegian Cruise Line Tumbles After Earnings Miss, Still Confident In 2025 Guidance</a></strong></li>
</ul>


IONS

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

<p>Lake Street  analyst Jaeson Schmidt   maintains Benchmark Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) with a Buy and lowers the price target from $52 to $46.</p>


Lake Street Maintains Buy on Benchmark Electronics, Lowers Price Target to $46

Visa Unveils Visa Intelligent Commerce, Enabling AI to Discover and Purchase Products at the Visa Global Product Drop

<p>Lake Street  analyst Eric Martinuzzi   maintains Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) with a Hold and raises the price target from $2.75 to $4.</p>


EVLV

Lake Street Maintains Hold on Evolv Technologies, Raises Price Target to $4

<p>Bank of the James Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTJ#NASDAQ">BOTJ</a>) reported quarterly earnings of $0.19 per share. This is a 60.42 percent decrease over earnings of $0.48 per share from the same period last year.  The company reported $11.00 million in sales this quarter. This is a 7.26 percent increase over sales of $10.26 million the same period last year.</p>


BOTJ

Bank of the James Finl Gr Q1 EPS $0.19 Down From $0.48 YoY, Sales $11.00M Up From $10.26M YoY

<p><strong>Acadian Asset Management</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAMI#NYSE">AAMI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Acadian Asset Management will report an <strong>earnings per share</strong> (EPS) of $0.50. </p>
<p>Investors in Acadian Asset Management are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.36, which was followed by a 0.08% increase in the share price the next day.</p>
<p>Here's a look at Acadian Asset Management's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.48</td>
<td>0.41</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.30</td>
<td>0.59</td>
<td>0.45</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>4.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036177_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Acadian Asset Management were trading at $26.69 as of April 29. Over the last 52-week period, shares are up 17.11%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Acadian Asset Management</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Acadian Asset Management.</p>
<p>With 3 analyst ratings, Acadian Asset Management has a consensus rating of Neutral. The average one-year price target is $25.33, indicating a potential 5.1% downside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Virtus Inv, P10 and WisdomTree, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Underperform trajectory for Virtus Inv, with an average 1-year price target of $183.14, suggesting a potential 586.17% upside.</li>
<li>Analysts currently favor an Outperform trajectory for P10, with an average 1-year price target of $14.0, suggesting a potential 47.55% downside.</li>
<li>Analysts currently favor an Sell trajectory for WisdomTree, with an average 1-year price target of $8.5, suggesting a potential 68.15% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Virtus Inv, P10 and WisdomTree are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acadian Asset Management</td>
<td>Neutral</td>
<td>27.90%</td>
<td>$91.70M</td>
<td>4047.62%</td>
</tr>
<tr>
<td>Virtus Inv</td>
<td>Underperform</td>
<td>-6.69%</td>
<td>$126.21M</td>
<td>3.20%</td>
</tr>
<tr>
<td>P10</td>
<td>Outperform</td>
<td>34.80%</td>
<td>$45.59M</td>
<td>1.51%</td>
</tr>
<tr>
<td>WisdomTree</td>
<td>Sell</td>
<td>21.85%</td>
<td>$57.81M</td>
<td>6.76%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Acadian Asset Management ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Discovering Acadian Asset Management: A Closer Look</h3>
<p>Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.</p>
<h3>A Deep Dive into Acadian Asset Management's Financials</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Acadian Asset Management displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>27.9%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Acadian Asset Management's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>25.33%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Acadian Asset Management's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4047.62%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Acadian Asset Management's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>6.75%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Acadian Asset Management's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>17.08</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/AAMI/earnings"><strong>To track all earnings releases for Acadian Asset Management visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AAMI

A Glimpse of Acadian Asset Management's Earnings Potential

<p>ACCO Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACCO#NYSE">ACCO</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate ACCO Brands to report an <strong>earnings per share</strong> (EPS) of $-0.04.</p>
<p>The market awaits ACCO Brands's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.02, leading to a 17.39% drop in the share price the following trading session.</p>
<p>Here's a look at ACCO Brands's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.41</td>
<td>0.23</td>
<td>0.31</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.39</td>
<td>0.23</td>
<td>0.37</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-17.0%</td>
<td>7.000000000000001%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036168_0.png" alt="eps graph" /></p>
<h3>Performance of ACCO Brands Shares</h3>
<p>Shares of ACCO Brands were trading at $3.92 as of April 29. Over the last 52-week period, shares are down 21.85%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Opinions on ACCO Brands</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ACCO Brands.</p>
<p>Analysts have given ACCO Brands a total of 1 ratings, with the consensus rating being Outperform. The average one-year price target is $7.0, indicating a potential 78.57% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Interface and MSA Safety, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Interface, with an average 1-year price target of $30.0, suggesting a potential 665.31% upside.</li>
<li>Analysts currently favor an Neutral trajectory for MSA Safety, with an average 1-year price target of $168.0, suggesting a potential 4185.71% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Interface and MSA Safety, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCO Brands</td>
<td>Outperform</td>
<td>-8.29%</td>
<td>$155.50M</td>
<td>3.37%</td>
</tr>
<tr>
<td>Interface</td>
<td>Outperform</td>
<td>3.04%</td>
<td>$122.31M</td>
<td>4.38%</td>
</tr>
<tr>
<td>MSA Safety</td>
<td>Neutral</td>
<td>0.88%</td>
<td>$234.43M</td>
<td>7.88%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>ACCO Brands ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.</p>
<h3>Discovering ACCO Brands: A Closer Look</h3>
<p>ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.</p>
<h3>Understanding the Numbers: ACCO Brands's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> ACCO Brands's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-8.29%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> ACCO Brands's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.6%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ACCO Brands's ROE excels beyond industry benchmarks, reaching <strong>3.37%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> ACCO Brands's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.9%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.52</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/ACCO/earnings"><strong>To track all earnings releases for ACCO Brands visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ACCO

What's Next: ACCO Brands's Earnings Preview

<p><strong>Quaker Houghton</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Quaker Houghton will report an <strong>earnings per share</strong> (EPS) of $1.61. </p>
<p>The announcement from Quaker Houghton is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.19, which was followed by a 2.61% increase in the share price the next day.</p>
<p>Here's a look at Quaker Houghton's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.52</td>
<td>2.11</td>
<td>2.21</td>
<td>1.99</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.33</td>
<td>1.89</td>
<td>2.13</td>
<td>2.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036159_0.png" alt="eps graph" /></p>
<h3>Quaker Houghton Share Price Analysis</h3>
<p>Shares of Quaker Houghton were trading at $105.98 as of April 29. Over the last 52-week period, shares are down 45.42%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Quaker Houghton</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Quaker Houghton.</p>
<p>The consensus rating for Quaker Houghton is Neutral, based on 4 analyst ratings. With an average one-year price target of $147.25, there's a potential 38.94% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Minerals Technologies, Perimeter Solutions and Innospec, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Minerals Technologies, with an average 1-year price target of $89.0, suggesting a potential 16.02% downside.</li>
<li>Analysts currently favor an Buy trajectory for Perimeter Solutions, with an average 1-year price target of $14.0, suggesting a potential 86.79% downside.</li>
<li>Analysts currently favor an Buy trajectory for Innospec, with an average 1-year price target of $155.0, suggesting a potential 46.25% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Minerals Technologies, Perimeter Solutions and Innospec, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quaker Houghton</td>
<td>Neutral</td>
<td>-4.93%</td>
<td>$156.20M</td>
<td>1.01%</td>
</tr>
<tr>
<td>Minerals Technologies</td>
<td>Buy</td>
<td>-7.99%</td>
<td>$119.60M</td>
<td>-8.61%</td>
</tr>
<tr>
<td>Perimeter Solutions</td>
<td>Buy</td>
<td>45.04%</td>
<td>$41.90M</td>
<td>13.36%</td>
</tr>
<tr>
<td>Innospec</td>
<td>Buy</td>
<td>-5.64%</td>
<td>$136.20M</td>
<td>-5.74%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Quaker Houghton ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Quaker Houghton is at the bottom compared to its peers.</p>
<h3>Unveiling the Story Behind Quaker Houghton</h3>
<p>Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.</p>
<h3>Understanding the Numbers: Quaker Houghton's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Quaker Houghton faced challenges, resulting in a decline of approximately <strong>-4.93%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Quaker Houghton's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>3.19%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Quaker Houghton's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.01%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Quaker Houghton's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.53%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.55</strong>, Quaker Houghton adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/KWR/earnings"><strong>To track all earnings releases for Quaker Houghton visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look at Quaker Houghton's Upcoming Earnings Report

<p>Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Velocity Financial will report an <strong>earnings per share</strong> (EPS) of $0.56.</p>
<p>The announcement from Velocity Financial is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.12, leading to a 8.47% increase in the share price on the subsequent day.</p>
<p>Here's a look at Velocity Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td>0.48</td>
<td>0.41</td>
<td>0.39</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.60</td>
<td>0.47</td>
<td>0.45</td>
<td>0.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>2.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036151_0.png" alt="eps graph" /></p>
<h3>Performance of Velocity Financial Shares</h3>
<p>Shares of Velocity Financial were trading at $17.87 as of April 29. Over the last 52-week period, shares are up 2.94%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/VEL/earnings"><strong>To track all earnings releases for Velocity Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: Velocity Financial's Quarterly Earnings

<p>Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Scorpio Tankers will report an <strong>earnings per share</strong> (EPS) of $2.65.</p>
<p>The market awaits Scorpio Tankers's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS missed by $0.02, leading to a 6.69% drop in the share price on the subsequent day.</p>
<p>Here's a look at Scorpio Tankers's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.65</td>
<td>2.10</td>
<td>3.59</td>
<td>3.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.63</td>
<td>1.75</td>
<td>3.60</td>
<td>3.97</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-2.0%</td>
<td>-0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036142_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Scorpio Tankers were trading at $37.8 as of April 29. Over the last 52-week period, shares are down 47.38%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Observations about Scorpio Tankers</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Scorpio Tankers.</p>
<p>The consensus rating for Scorpio Tankers is Buy, derived from 3 analyst ratings. An average one-year price target of $61.33 implies a potential 62.25% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Global Partners, DHT Holdings and Frontline, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Global Partners, with an average 1-year price target of $56.0, suggesting a potential 48.15% upside.</li>
<li>Analysts currently favor an Buy trajectory for DHT Holdings, with an average 1-year price target of $13.5, suggesting a potential 64.29% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Frontline, with an average 1-year price target of $20.0, suggesting a potential 47.09% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Global Partners, DHT Holdings and Frontline are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scorpio Tankers</td>
<td>Buy</td>
<td>-39.35%</td>
<td>$66.11M</td>
<td>2.40%</td>
</tr>
<tr>
<td>Global Partners</td>
<td>Neutral</td>
<td>-5.05%</td>
<td>$268.83M</td>
<td>2.47%</td>
</tr>
<tr>
<td>DHT Holdings</td>
<td>Buy</td>
<td>-8.36%</td>
<td>$38.56M</td>
<td>5.31%</td>
</tr>
<tr>
<td>Frontline</td>
<td>Outperform</td>
<td>2.56%</td>
<td>$113.58M</td>
<td>2.85%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Scorpio Tankers ranks at the bottom for Revenue Growth, with the lowest percentage among peers. It also has the lowest Gross Profit among the group. However, it has the highest Return on Equity, indicating strong performance in this aspect compared to its peers.</p>
<h3>Discovering Scorpio Tankers: A Closer Look</h3>
<p>Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.</p>
<h3>Financial Milestones: Scorpio Tankers's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Scorpio Tankers's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-39.35%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Scorpio Tankers's net margin excels beyond industry benchmarks, reaching <strong>33.61%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.4%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Scorpio Tankers's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.78%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Scorpio Tankers's debt-to-equity ratio is below the industry average. With a ratio of <b>0.3</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/STNG/earnings"><strong>To track all earnings releases for Scorpio Tankers visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


STNG

Scorpio Tankers's Earnings: A Preview

<p>Savers Value Village (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Savers Value Village to report an <strong>earnings per share</strong> (EPS) of $0.07.</p>
<p>The announcement from Savers Value Village is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.03, leading to a 19.45% drop in the share price on the subsequent day.</p>
<p>Here's a look at Savers Value Village's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.13</td>
<td>0.16</td>
<td>0.20</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.10</td>
<td>0.15</td>
<td>0.14</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-19.0%</td>
<td>-8.0%</td>
<td>-9.0%</td>
<td>-20.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036127_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Savers Value Village were trading at $9.3 as of April 29. Over the last 52-week period, shares are down 41.58%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analyst Views on Savers Value Village</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Savers Value Village.</p>
<p>The consensus rating for Savers Value Village is Neutral, based on 3 analyst ratings. With an average one-year price target of $10.67, there's a potential 14.73% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and Savers Value Village, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for  and Savers Value Village, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Savers Value Village</td>
<td>Neutral</td>
<td>5.02%</td>
<td>$223.81M</td>
<td>-0.44%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Savers Value Village ranks in the middle among peers for consensus rating. It is at the bottom for revenue growth, indicating slower growth compared to peers. The company's gross profit is also at the bottom, suggesting lower profitability. Additionally, its return on equity is negative, reflecting poor performance in utilizing shareholder equity.</p>
<h3>Get to Know Savers Value Village Better</h3>
<p>Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, merchandise, and sells these items in its stores.</p>
<h3>Savers Value Village: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Savers Value Village displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>5.02%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Savers Value Village's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-0.47%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Savers Value Village's ROE excels beyond industry benchmarks, reaching <strong>-0.44%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Savers Value Village's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.1%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Savers Value Village's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.09</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/SVV/earnings"><strong>To track all earnings releases for Savers Value Village visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Savers Value Village's Upcoming Earnings

<p>Beazer Homes USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Beazer Homes USA will report an <strong>earnings per share</strong> (EPS) of $0.29.</p>
<p>Investors in Beazer Homes USA are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS missed by $0.21 in the last quarter, leading to a 20.0% drop in the share price on the following day.</p>
<p>Here's a look at Beazer Homes USA's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.31</td>
<td>1.35</td>
<td>0.83</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.10</td>
<td>1.69</td>
<td>0.88</td>
<td>1.26</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-20.0%</td>
<td>8.0%</td>
<td>-13.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036100_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Beazer Homes USA were trading at $19.35 as of April 29. Over the last 52-week period, shares are down 28.23%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BZH/earnings"><strong>To track all earnings releases for Beazer Homes USA visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview: Beazer Homes USA

<p>PBF Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that PBF Energy will report an <strong>earnings per share</strong> (EPS) of $-2.66.</p>
<p>PBF Energy bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.04, leading to a 0.04% drop in the share price the following trading session.</p>
<p>Here's a look at PBF Energy's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-2.78</td>
<td>-1.41</td>
<td>-0.15</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-2.82</td>
<td>-1.50</td>
<td>-0.54</td>
<td>0.85</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036091_0.png" alt="eps graph" /></p>
<h3>PBF Energy Share Price Analysis</h3>
<p>Shares of PBF Energy were trading at $17.22 as of April 29. Over the last 52-week period, shares are down 67.41%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Perspectives on PBF Energy</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding PBF Energy.</p>
<p>The consensus rating for PBF Energy is Neutral, based on 10 analyst ratings. With an average one-year price target of $23.4, there's a potential 35.89% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of CVR Energy, World Kinect and Delek US Hldgs, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for CVR Energy, with an average 1-year price target of $17.67, suggesting a potential 2.61% upside.</li>
<li>Analysts currently favor an Neutral trajectory for World Kinect, with an average 1-year price target of $28.0, suggesting a potential 62.6% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Delek US Hldgs, with an average 1-year price target of $16.2, suggesting a potential 5.92% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for CVR Energy, World Kinect and Delek US Hldgs, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBF Energy</td>
<td>Neutral</td>
<td>-19.56%</td>
<td>$-308.50M</td>
<td>-5.06%</td>
</tr>
<tr>
<td>CVR Energy</td>
<td>Neutral</td>
<td>-11.58%</td>
<td>$56M</td>
<td>4.21%</td>
</tr>
<tr>
<td>World Kinect</td>
<td>Neutral</td>
<td>-13.69%</td>
<td>$230.40M</td>
<td>-1.09%</td>
</tr>
<tr>
<td>Delek US Hldgs</td>
<td>Neutral</td>
<td>-39.79%</td>
<td>$-140.80M</td>
<td>-81.46%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>PBF Energy ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. In terms of Return on Equity, PBF Energy is at the bottom compared to its peers. Overall, PBF Energy lags behind its peers in key financial metrics.</p>
<h3>All You Need to Know About PBF Energy</h3>
<p>PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines and storage facilities. The Logistics segment consists solely of PBFX's operations.</p>
<h3>PBF Energy: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> PBF Energy's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-19.56%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> PBF Energy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-3.94%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> PBF Energy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-5.06%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> PBF Energy's ROA excels beyond industry benchmarks, reaching <strong>-2.24%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> PBF Energy's debt-to-equity ratio is below the industry average at <strong>0.42</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/PBF/earnings"><strong>To track all earnings releases for PBF Energy visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into PBF Energy's Upcoming Earnings

<p>Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Agios Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $-1.76.</p>
<p>The announcement from Agios Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.31, leading to a 0.24% drop in the share price on the subsequent day.</p>
<p>Here's a look at Agios Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.63</td>
<td>1.11</td>
<td>-1.59</td>
<td>-1.65</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.94</td>
<td>-1.43</td>
<td>-1.69</td>
<td>-1.45</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036078_0.png" alt="eps graph" /></p>
<h3>Performance of Agios Pharmaceuticals Shares</h3>
<p>Shares of Agios Pharmaceuticals were trading at $29.1 as of April 29. Over the last 52-week period, shares are down 14.84%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Take on Agios Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Agios Pharmaceuticals.</p>
<p>Analysts have given Agios Pharmaceuticals a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $58.0, indicating a potential 99.31% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Arcutis Biotherapeutics, Galapagos and Travere Therapeutics, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Arcutis Biotherapeutics, with an average 1-year price target of $19.12, suggesting a potential 34.3% downside.</li>
<li>Analysts currently favor an Underperform trajectory for Galapagos, with an average 1-year price target of $22.0, suggesting a potential 24.4% downside.</li>
<li>Analysts currently favor an Buy trajectory for Travere Therapeutics, with an average 1-year price target of $40.75, suggesting a potential 40.03% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Arcutis Biotherapeutics, Galapagos and Travere Therapeutics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agios Pharmaceuticals</td>
<td>Buy</td>
<td>51.06%</td>
<td>$9.47M</td>
<td>-6.09%</td>
</tr>
<tr>
<td>Arcutis Biotherapeutics</td>
<td>Buy</td>
<td>427.58%</td>
<td>$64.45M</td>
<td>-6.87%</td>
</tr>
<tr>
<td>Galapagos</td>
<td>Underperform</td>
<td>20.09%</td>
<td>$61.25M</td>
<td>-5.44%</td>
</tr>
<tr>
<td>Travere Therapeutics</td>
<td>Buy</td>
<td>65.98%</td>
<td>$72.23M</td>
<td>-421.09%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Agios Pharmaceuticals ranks at the bottom for Revenue Growth and Gross Profit among its peers. It also has the lowest Return on Equity.</p>
<h3>Get to Know Agios Pharmaceuticals Better</h3>
<p>Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.</p>
<h3>Agios Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Agios Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>51.06%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Agios Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of <strong>-899.56%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Agios Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-6.09%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-5.59%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.04</strong>, Agios Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/AGIO/earnings"><strong>To track all earnings releases for Agios Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AGIO

An Overview of Agios Pharmaceuticals's Earnings

<p>26 analysts have shared their evaluations of Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $360.65, a high estimate of $500.00, and a low estimate of $275.00. A decline of 9.87% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746036071_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Lululemon Athletica's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$300.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$302.00</td>
<td>$363.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$389.00</td>
<td>$391.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$353.00</td>
<td>$424.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$297.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$373.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$380.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$302.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$309.00</td>
<td>$411.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$335.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$424.00</td>
<td>$438.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$315.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$391.00</td>
<td>$437.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$366.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$385.00</td>
<td>$445.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$430.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$330.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$445.00</td>
<td>$445.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$411.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Brian Nagel</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$380.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lululemon Athletica. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lululemon Athletica compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lululemon Athletica's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LULU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lululemon Athletica analyst ratings.</strong></a></p>
<h2>Get to Know Lululemon Athletica Better</h2>
<p>Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 760 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 40 franchised locations in the Middle East. The company was founded in 1998 and is based in Vancouver, Canada.</p>
<h3>Key Indicators: Lululemon Athletica's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Lululemon Athletica's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of <strong>12.68%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Lululemon Athletica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>20.72%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Lululemon Athletica's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>18.01%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Lululemon Athletica's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.19%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.36</strong>, Lululemon Athletica adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LULU

Where Lululemon Athletica Stands With Analysts

Press Releases

Ultra-Core Ignition, A Lavish Leap into the Future BUTTONS CLIP Earphones Make a Dazzling Debut: Powered by an AI-Driven Strategy, Pioneering the Future of Intelligent Luxury

Film Director Madi Boll Shares Her Journey from Concordia Shanghai to Hollywood

Blue Sky Scrubs Celebrates International Women's Day with a Special Giveaway Honoring Women in Healthcare

Accutone® Revamps Wired Headsets with Converse Series, Poised to Boom in the Professional Headset Market – Arizton

Belgium Data Center Market Investment to Worth $3.11 Billion by 2030 – With Brussels Leading the Charge – Arizton

Top Debt Collection Agency Helping London Businesses Stay Afloat

Fivalo: Precision, Purpose, and the Future of Woodworking Innovation

Global Hospitality Giants Marriott and Hilton Drive Growth in Health & Wellness Spa Market with New Luxury Resort Launches – Arizton

Tech Giants Expand Footprint as Switzerland Becomes Data Infrastructure Hotspot – Investment to Reach $1.99 Billion by 2030 – Arizton

Pallet Trucks UK Announces Launch of Built-to-Last TRITON Brand

Avalon Globocare

American Realty Investors, Inc. Common Stock

American Realty Investors

CKX Lands

FRP Holdings

New Concept Energy

The Intergroup Corporation - Common Stock

Intergroup

IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of Common Stock)

IRSA Inversiones y

Kennedy-Wilson Holdings Inc. Common Stock

Kennedy-Wilson Holdings

LandBridge Company LLC Class A Shares Representing Limited Liability Company Interests

LandBridge

Logistic Properties of the Americas Ordinary Shares

Logistic Properties

Maui Land & Pineapple Company, Inc. Common Stock

Maui Land & Pineapple Co

Murano Global Investments PLC - Ordinary Shares

Murano Global Investments

New England Realty Associates Limited Partnership Class A Depositary Receipts Evidencing Units of Limited Partnership

New England Realty

American Strategic Investment Co. Class A Common Stock

American Strategic

Belpointe PREP

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Reitar Logtech Holdings Limited - Ordinary shares

Reitar Logtech Holdings

Seaport Entertainment Group Inc. Common Stock

Seaport Entertainment

Seritage Growth Properties Class A Common Stock

Seritage Growth Props

Transcontinental Realty Investors, Inc. Common Stock

Transcontinental Realty

Corporacion Inmobiliaria Vesta, S.A.B de C.V. American Depositary Shares, each representing ten (10) Common Shares

Comments

Ucommune International

Notizie

Ultime notizie per Ucommune International (NASDAQ:UK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO